CTOs on the Move

Aruvant

www.aruvant.com

 
Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aruvant.com
  • 151 West 42nd Street, 15th Floor
    New York, NY USA 10036
  • Phone: 646.495.5310

Executives

Name Title Contact Details

Similar Companies

ReviveRX

ReviveRX is a leading licensed mail-order pharmacy specializing in generic and compounded medications. Our compounds are expertly crafted in USP-certified clean rooms at our Houston headquarters, ensuring the highest quality standards. We work closely with best-in-class pharmacists, scientists, healthcare providers, and pharmaceutical manufacturers to provide high-quality, dependable products to our patients and clinic partners.

Barc USA

Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.

Epinex Diagnostics

Epinex Diagnostics is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cue

Our mission is to create tools that empower physicians and consumers by increasing their access to actionable data.